Table 2

FDA-approved JAK inhibitors

DrugTargetFDA approval
RuxolitinibJAK1, JAK2Myelofibrosis, polycythemia vera, acute graft-versus-host disease
BaricitinibJAK1, JAK2Rheumatoid arthritis
TofacitinibJAK3>JAK1>>(JAK2)Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, polyarticular juvenile idiopathic arthritis
PeficitinibJAK1, JAK3>JAK2Under evaluation by FDA, approved in Japan and Korea for rheumatoid arthritis
UpadacitinibJAK1Rheumatoid arthritis
OclacitinibJAK1Atopic dermatitis in dogs
FedratinibJAK2Myelofibrosis

  • FDA, Food and Drug Administration; JAK, janus kinase.